We are planning to grant individualized attention to several important topics in the area of antibacterial drug discovery and development, and we are coming up with a series of short courses that will each be dedicated to a separate issue, technology or platform. Our goal is to offer additional coverage and to allow networking and opinion exchange in the more intimate class room environment setting.

Dinner Short Courses

December 7, 6:30 pm – 9:30 pm

SC1: From “White Powder” to Drug: The Path from Antibacterial Discovery to the Clinic* - Detailed Agenda

Chairperson and Moderator:
Lynn Silver, Ph.D., Silver Consulting, LLC

The course will cover:

• Compound validation
• Aileen Rubio, Ph.D., Head of Biology, Spero Therapeutics
• Preclinical development
• Joyce Sutcliff, Ph.D., Former Senior Vice President, Biology, Tetraphase Pharmaceuticals, Inc.
• Clinical phases
•  Robin Isaacs, MD, Chief Medical Officer, Entasis Therapeutics
• Regulatory concerns and pathways
• Nicole Mahoney, Director, Global Policy, Merck
• Partnership seeking
• Vikas Goyal, Associate, SR One

December 8, 6:00 pm – 9:00 pm

SC2: Funding Opportunities for Antibacterial Research* - Detailed Agenda

Instructors:

Rosemarie Aurigemma, Ph.D., Chief, Drug Development Section, DMID, NIAID

Christopher Houchens, Ph.D., Branch Chief (Acting), Antibacterials Program,Division of CBRN Countermeasures, Biomedical Advanced Research and Development Authority (BARDA)

Amanda Horstman Smith, Ph.D., Science and Technology Manager

Defense Threat Reduction Agency

The course will cover:

• From basic research to the clinic – how do we support the discovery & development of new agents?
• Grants, contracts and biodefense partnerships
• Preclinical, nonclinical, and clinical product development services

*Separate Registration Required